Supernus Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Supernus Pharmaceuticals, Inc. (SUPN) develops and commercializes products for the treatment of central nervous system (CNS) disorders, epilepsy, and other neurological conditions. The company offers a portfolio of branded products including Trokendi XR (extended-release topiramate) for epilepsy and migraine prevention; Oxtellar XR (extended-release oxcarbazepine) for partial seizure treatment; Qudexy XR (extended-release topiramate) for epilepsy and migraine prophylaxis; and SPN-817, an investigational product in clinical development for treatment-resistant epilepsy. Additional pipeline candidates include SPN-830 (apomorphine infusion device for Parkinson's disease motor fluctuations) and SPN-820 (viloxazine extended-release for major depressive disorder), with research focused on novel formulations and delivery systems for CNS therapeutics. Supernus operates primarily in the United States, with headquarters in Rockville, Maryland, where it was founded in 2005. In recent developments, Supernus strengthened its epilepsy portfolio through the 2024 FDA approval and launch of a generic equivalent to Epidiolex (cannabidiol oral solution), expanding access to treatments for rare epilepsy syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. The company also advanced its pipeline with positive topline results from the Phase 3 trial of SPN-817 in mid-2025, supporting a New Drug Application submission planned for late 2025, and initiated a strategic collaboration with a leading device manufacturer for the SPN-830 infusion pump commercialization. No major acquisitions, funding rounds, or reorganizations have been reported in the last two years, allowing focus on organic growth and regulatory milestones in the competitive CNS pharmaceuticals segment targeting neurologists, epileptologists, and pediatric specialists.
Supernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus Announces First Quarter 2026 Financial Results
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Cross Above 200-Day Moving Average – Should You Sell?
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Consensus PT from Brokerages
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year
Frederick Hudson Sells 5,369 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc.
American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN